Related Experiment Videos
Real-world outcomes of immunotherapy in advanced NSCLC patients with comorbidities
H H Hektoen1,2, K M Tsuruda3, M T Mæhlen4
1Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway. helga.helseth.hektoen@fhi.no.
Background:
Comorbidities are common in advanced non-small cell lung cancer (NSCLC) patients, yet their impact on systemic anti-cancer treatment (SACT) and survival in the era of immune checkpoint inhibitors (ICIs) remains unclear due to limited representation in clinical trials.
Methods:
This nationwide registry-based study included 9178 patients with stage IIIB-IV NSCLC diagnosed before and after ICI introduction. Kaplan-Meier and multivariable Cox models were applied to calculate hazard ratios (HRs) and 95% confidence intervals (CIs).
Results:
Common comorbidities included chronic obstructive pulmonary disease (COPD: 22%), cardiovascular disease (CVD: 21%), type 2 diabetes (T2D: 10%), and rheumatic and musculoskeletal diseases (RMD: 6%). Patients with comorbidities were less likely to receive SACT. Following ICI introduction, SACT use increased across all comorbidity groups and 2-year OS improved up to threefold. CVD patients had better 2-year OS when treated with ICI alone than ICI plus chemotherapy (38 vs 22%). Patients with CVD, T2D and RMD had higher risk of death when treated with ICI plus chemotherapy compared to patients without these comorbidities (HR = 1.36 (1.07-1.73), HR = 1.33 (0.99-1.78) and HR = 1.38 (0.97-1.95), respectively).
Conclusions:
Survival among patients with comorbidities improved following ICI introduction, however the benefit varied by comorbidity and treatment modality, supporting more individualised treatment strategies.
Related Concept Videos
Tumor Immunotherapy
Treatment Resistent Cancers
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...